Condition

Acute Myelomonocytic Leukemia

Condition 101

What are the alternative names for Acute Myelomonocytic Leukemia?

AML-M4
Acute myeloblastic leukemia type 4
AML M4
AMMoL

Learn More About This Condition

Top Global Doctors

Marseille, 93, FR

Mrinal M. Patnaik

Internal Medicine

Seishi K. Ogawa

Internal Medicine

Roland B. Walter

Internal Medicine

Mikkael A. Sekeres

Internal Medicine

View All Doctors

Latest Research

Latest Advance

Study

Condition: Therapy-Related Myeloid Neoplasms
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Treatment Used: Allogeneic Stem Cell Transplantation
Number of Patients: 12169
Published — April 23, 2020

This study tested the safety and efficacy of using allogeneic stem cell transplantation to treat patients with therapy-related myeloid neoplasms.

Latest Advance

Study

Condition: Patients with Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN)
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Treatment Used: Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation (allo-HSCT)
Number of Patients: 48
Published — September 09, 2019

This study assessed the effectiveness of a new conditioning regimen comprising decitabine (Dec), busulfan (Bu), cyclophosphamide (Cy), fludarabine (Flu), and cytarabine (Ara-c) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN).

Latest Advance

Study

Condition: Myelodysplastic syndrome and chronic myelomonocytic leukemia
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Treatment Used: Decitabine-based conditioning regimen
Number of Patients: 22
Published — July 26, 2019

The aim of the study was to assess the effectiveness and toxicity of decitabine-based conditioning regimen in patients with myelodysplastic syndrome (MDS), acute myeloid leukemia secondary to MDS (MDS-AML) or chronic myelomonocytic leukemia (CMML).

Latest Advance

Study

Condition: Juvenile Myelomonocytic Leukemia
Journal: Pediatric blood & cancer
Treatment Used: Azacitidine
Number of Patients: 1
Published — June 29, 2019

This case reported on an infant with juvenile myelomonocytic leukemia treated with azacitidine.

View All Latest Research

Clinical Trials

Clinical Trial

Drug

Status: Recruiting
Study Type: Drug
Participants: 72
Start Date: October 3, 2020

CLAG·M Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study

Clinical Trial

Biological

Status: Recruiting
Study Type: Biological
Participants: 60
Start Date: August 25, 2020

Phase 2, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1B Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Clinical Trial

Drug

Status: Recruiting
Study Type: Drug
Participants: 58
Start Date: July 21, 2020

Phase I/II Study of Azacitidine in Combination With Quizartinib for Patients With Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms With FLT3 or CBL Mutations

Clinical Trial

Drug

Status: Recruiting
Study Type: Drug
Participants: 40
Start Date: July 21, 2020

A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

View All Clinical Trials